Navigation Links
Aeterna Zentaris Reports Third Quarter 2010 Financial and Operating Results
Date:11/9/2010

ed September 30, 2010, compared to $8.6 million for the same period in 2009. The decrease is due mainly to the absence, in 2010, of amortization of an upfront license fee payment related to our agreement with sanofi-aventis U.S. LLC, which was entered into in March 2009 and subsequently terminated, in connection with our now discontinued development program involving cetrorelix for the treatment of benign prostatic hyperplasia ("BPH"). Research and development ("R&D") costs, net of tax credits and grants, were $4.1 million for the three-month period ended September 30, 2010, compared to $9.7 million for the same period in 2009. The comparative decrease in net R&D costs is primarily attributable to the winding down and termination of development activities related to cetrorelix in BPH. Net losswas $10.1 million, or $0.12 per basic and diluted share, for the three-month period ended September 30, 2010, compared to $11.3 million, or $0.19 per basic and diluted share, for the same period in 2009. The decrease in net loss is attributable largely to lower net R&D expenses and to lower SG&A expenses, despite both the comparative decrease in revenues and the comparative increase in foreign exchange losses. Cash and cash equivalents totalled $39.9 million as at September 30, 2010. Conference call Management will be hosting a conference call for the investment community beginning at 4:00 p.m. Eastern Time today, Tuesday, November 9, 2010, to discuss third quarter 2010 results. Individuals interested in participating in the live conference call by telephone may dial, in Canada, 514-807-9895 or 647-427-7450, from outside Canada, 888-231-8191 or may listen through the Internet at www.aezsinc.com in the Newsroom section. A replay will be available on the Company's website for 30 days following the live event. About Aeterna Zentaris Inc. Aeterna Zentaris is a late-st
'/>"/>
SOURCE AETERNA ZENTARIS INC.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. AEterna Zentaris Announces Appointment of Prof. Jurgen Engel, Ph.D. as New President and CEO
2. AEterna Zentaris Reports Second Quarter 2008 Financial and Operating Results
3. AEterna Zentaris to Present at Upcoming CIBC World Markets 7th Annual Eastern Investor Conference
4. AEterna Zentaris to Present at BioContact Quebec on October 2, 2008
5. AEterna Zentaris Completes Patient Recruitment for Second Efficacy Trial of its Phase 3 Program with Cetrorelix in Benign Prostatic Hyperplasia
6. AEterna Zentaris Receives Notification from Nasdaq Relating to Minimum Bid Price
7. AEterna Zentaris to Present at Upcoming Oppenheimer 19th Annual Healthcare Conference
8. AEterna Zentaris Reaches 2nd Stage of Patient Recruitment for Phase 2 Trial in Endometrial Cancer with the Innovative LHRH Receptor Targeted Conjugate, AEZS-108
9. AEterna Zentaris Agrees to Sell Cetrotide(R) Royalty Stream for $52.5 Million to Cowen Healthcare Royalty Partners
10. AEterna Zentaris to Announce Third Quarter 2008 Financial and Operating Results on November 13, 2008
11. AEterna Zentaris Reports Third Quarter 2008 Financial and Operating Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... NY (PRWEB) September 18, 2014 Whitehouse ... negotiations with Salem Realty Group and has acquired an ... space within the Salem Executive Complex adjacent to its ... was held on Friday September 5th. Whitehouse Labs is ... the entire space specifically for package testing. The prime ...
(Date:9/17/2014)... Sept. 17, 2014 /PRNewswire/ - Oncothyreon Inc. (NASDAQ: ... offer and sell shares of its Common Stock and ... underwritten public offerings.  The Series A Convertible Preferred Stock ... Stock, provided that conversion will be prohibited if, as ... own more than 4.99% of the Common Stock then ...
(Date:9/17/2014)... , Sept. 17, 2014  MiMedx Group, Inc. (NASDAQ: ... and marketer of patent protected regenerative biomaterials and ... publication of another peer-reviewed clinical study.    ... Multi-center Randomized Controlled Clinical Trial Evaluating the Use ... Allografts and Multi-layer Compression Therapy vs. Multi-layer Compression ...
(Date:9/17/2014)... 17, 2014 Immunomic Therapeutics, Inc. announced ... (SBIR) grant to support the continued preclinical development of ... with approximately $255,000 over one year to conduct vaccine ... food allergy, affect over one million Americans and are ... Tree nut exposure is also a risk for peanut ...
Breaking Biology Technology:Whitehouse Labs Announces Package Testing Laboratory Expansion 2Whitehouse Labs Announces Package Testing Laboratory Expansion 3Whitehouse Labs Announces Package Testing Laboratory Expansion 4Oncothyreon Announces Proposed Public Offerings 2MiMedx Multi-Center Randomized, Controlled VLU Clinical Study Published In Peer-Reviewed Journal 2MiMedx Multi-Center Randomized, Controlled VLU Clinical Study Published In Peer-Reviewed Journal 3MiMedx Multi-Center Randomized, Controlled VLU Clinical Study Published In Peer-Reviewed Journal 4Immunomic Therapeutics Awarded SBIR Grant to Develop Multi-Nut Allergy Immunotherapy 2Immunomic Therapeutics Awarded SBIR Grant to Develop Multi-Nut Allergy Immunotherapy 3
... 2011 Amylin Pharmaceuticals, Inc. (Nasdaq: ... for 2011, highlighting its continued focus on strong ... Company,s diabetes franchise, notably through advancing the investigational ... other value-driving development programs. Daniel M. Bradbury, president ...
... BioLife Solutions, Inc. (OTC Bulletin Board: BLFS ) ... and Chief Executive Officer Mike Rice, to summarize the continued ... strategic growth initiatives.   (Logo:   http://photos.prnewswire.com/prnh/20090814/BIOLIFELOGO ) ... of $575,000 for the fourth quarter of 2010, an increase ...
... The Jackson Laboratory (JAX), Sackler School of Graduate Biomedical Sciences ... a new mammalian genetics track for Ph.D. students. The joint ... and Tufts. Combining the faculty and resources of the genetics ... the faculty and resources at JAX, with its emphasis on ...
Cached Biology Technology:Amylin to Advance Key Value-Driving Opportunities in 2011 2Amylin to Advance Key Value-Driving Opportunities in 2011 3BioLife Solutions CEO Issues 2010 Corporate Update 2BioLife Solutions CEO Issues 2010 Corporate Update 3The Jackson Laboratory and Tufts University Announce New Ph.D. Track in Mammalian Genetics 2The Jackson Laboratory and Tufts University Announce New Ph.D. Track in Mammalian Genetics 3
(Date:9/17/2014)... have obtained the first partial genome sequence of an ... at the site of the Montsoriu Castle in Girona, ... closely related to today,s Iberian pig. Researchers also discard ... Iberian pigs. , The study, published in Heredity ... species, and particularly on that of the Iberian breed, ...
(Date:9/17/2014)... September 17, 2014 Researchers at UTSouthwestern Medical ... the circulating protein apolipoprotein E, called apoE3, helps repair ... called apoE4, do not get the benefit of this ... , "We believe that we have identified one mechanism ... why a genetic variant, apoE4, is detrimental," said ...
(Date:9/17/2014)... 1960s. The typical development phases of trees and stands ... as much as 70 percent. This was the outcome ... Universitt Mnchen based on long-term data from experimental forest ... findings were published recently in Nature Communications . ... topic, with the very survival of large forest ecosystems ...
Breaking Biology News(10 mins):Iberian pig genome remains unchanged after 5 centuries 2Protein variant may boost cardiovascular risk by hindering blood vessel repair 2Global change: Trees continue to grow at a faster rate 2Global change: Trees continue to grow at a faster rate 3
... a new biological pathway-based computational model, called the Pathway-based ... between different diseases as reported in BioDataMining ... present in large publicly available disease datasets to find ... a visual form. "The PHPN offers a bird,s ...
... 11 million people suffer severe burns. The resulting large, deep ... lifelong scars. What is needed to reduce this kind of ... very limited area of skin can be removed from the ... Besides conventional skin grafting, another option is to engineer a ...
... to finding cures for heart disease scientists are working to ... a tissue model for the human heart that can bridge ... exist for other organs, but for the heart, this has ... embryonic stem cells with the resulting muscle having significant similarities ...
Cached Biology News:Dartmouth researchers develop new tool to identify genetic risk factors 2Blood and lymphatic capillaries grown for the first time in the lab 2Scientists develop an engineered cardiac tissue model to study the human heart 2
... offers major advantages over other RNA precipitation methods ... or carbohydrates. It is the method of choice ... from RNA preparations. Note, LiCl precipitation may not ... If the RNA is to be used for ...
... Antifade Kit is an aqueous-based mounting reagent ... dyes. This formulation of antifade minimizes the ... Blue fluorophores that is often seen with ... available with the blue-fluorescent nucleic acid ...
in vitro Translation, Accessory Products...
Mouse Collagen IV...
Biology Products: